{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:44:47Z","timestamp":1793781887113,"version":"4.6.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CX002396"],"award-info":[{"award-number":["CX002396"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","cghjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.cgh.2024.05.051","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T05:24:00Z","timestamp":1721885040000},"page":"469-479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["IBD Matchmaking: Rational Combination Therapy"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7421-9764","authenticated-orcid":false,"given":"Robert","family":"Battat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Edward V.","family":"Loftus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5762-5042","authenticated-orcid":false,"given":"Bruce E.","family":"Sands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2024.05.051_bib1","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1056\/NEJMra2002697","article-title":"Pathophysiology of inflammatory bowel diseases","volume":"383","author":"Chang","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2024.05.051_bib2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nri3661","article-title":"Cytokines in inflammatory bowel disease","volume":"14","author":"Neurath","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.cgh.2024.05.051_bib3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41575-023-00768-1","article-title":"IL-12 and IL-23 pathway inhibition in inflammatory bowel disease","volume":"20","author":"Verstockt","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.05.051_bib4","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq4473","article-title":"Targeting cytokines in inflammatory bowel disease","volume":"14","author":"Neurath","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cgh.2024.05.051_bib5","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2024.05.051_bib6","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/ibd\/izaa277","article-title":"Dual biologic and small molecule therapy for the treatment of refractory pediatric inflammatory bowel disease","volume":"27","author":"Dolinger","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2024.05.051_bib7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/ecco-jcc\/jjaa149","article-title":"Dual targeted therapy: a possible option for the management of refractory inflammatory bowel disease","volume":"15","author":"Privitera","year":"2021","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.05.051_bib8","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/MCG.0000000000001583","article-title":"Dual targeted therapy for the management of inflammatory bowel disease","volume":"55","author":"Haider","year":"2021","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cgh.2024.05.051_bib9","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1136\/gutjnl-2022-327025","article-title":"The future of drug development for inflammatory bowel disease: the need to ACT (advanced combination treatment)","volume":"71","author":"Danese","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2024.05.051_bib10","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/gut.2004.060103","article-title":"Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild\/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study","volume":"54","author":"Marteau","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2024.05.051_bib11","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.cgh.2018.09.033","article-title":"Combination therapy with infliximab and azathioprine improves infliximab pharmacokinetic features and efficacy: a post hoc analysis","volume":"17","author":"Colombel","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.05.051_bib12","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1513\/pats.200504-037SR","article-title":"Pharmacologic principles for combination therapy","volume":"2","author":"Toews","year":"2005","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.cgh.2024.05.051_bib13","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1053\/j.gastro.2021.04.068","article-title":"Rational combination therapy to overcome the plateau of drug efficacy in inflammatory bowel disease","volume":"161","author":"Stalgis","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.05.051_bib14","first-page":"251","article-title":"Advanced combination treatment with biologic agents and novel small molecule drugs for inflammatory bowel disease","volume":"19","author":"Solitano","year":"2023","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.cgh.2024.05.051_bib15","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1182\/blood.V26.5.642.642","article-title":"The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia","volume":"26","author":"Frei","year":"1965","journal-title":"Blood"},{"key":"10.1016\/j.cgh.2024.05.051_bib16","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.molcel.2020.05.031","article-title":"Rational cancer treatment combinations: an urgent clinical need","volume":"78","author":"Boshuizen","year":"2020","journal-title":"Mol Cell"},{"key":"10.1016\/j.cgh.2024.05.051_bib17","series-title":"UpToDate","article-title":"Systemic therapy for nonoperable metastatic colorectal cancer: selecting the initial therapeutic approach","author":"Clark JWS","year":"2024"},{"key":"10.1016\/j.cgh.2024.05.051_bib18","series-title":"UpToDate","article-title":"Systemic therapy for nonoperable metastatic colorectal cancer: approach to later lines of systemic therapy","author":"Clark JWS","year":"2024"},{"key":"10.1016\/j.cgh.2024.05.051_bib19","series-title":"Antibiotic resistance threats in the United States, 2019","year":"2019"},{"key":"10.1016\/j.cgh.2024.05.051_bib20","series-title":"A\u00a0Rational Approach to Clinical Infectious Diseases: A Manual for House Officers and Other Non-Infectious Disease Clinicians","article-title":"I.C. General Principles of Antimicrobial Therapy","author":"ten Oever","year":"2021"},{"key":"10.1016\/j.cgh.2024.05.051_bib22","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(23)01525-8","article-title":"Rheumatoid arthritis","volume":"402","author":"Di","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2024.05.051_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000870","article-title":"van der Helm-van Mil AH. Window of opportunity in rheumatoid arthritis - definitions and supporting evidence: from old to new perspectives","volume":"5","author":"Burgers","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.cgh.2024.05.051_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2023.105578","article-title":"Rationale, current state and opportunities in combining biologic disease modifying antirheumatic drugs in rheumatoid and psoriatic arthritis","volume":"90","author":"Mutlu","year":"2023","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.cgh.2024.05.051_bib25","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jaad.2020.07.087","article-title":"Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures","volume":"84","author":"Elmets","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.cgh.2024.05.051_bib26","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.cgh.2024.05.051_bib27","first-page":"1867","article-title":"A\u00a0double--blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis","volume":"92","author":"Safdi","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.05.051_bib28","doi-asserted-by":"crossref","first-page":"733","DOI":"10.14309\/ajg.0000000000000111","article-title":"Histologic healing rates of medical therapies for ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials","volume":"114","author":"Battat","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.05.051_bib29","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.05.051_bib30","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2024.05.051_bib31","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","article-title":"Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases","volume":"155","author":"Kirchgesner","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.05.051_bib32","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.cgh.2017.03.032","article-title":"Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn\u2019s disease","volume":"15","author":"Battat","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.05.051_bib33","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1007\/s10620-017-4549-3","article-title":"Predictors of clinical response and remission at 1 year among a multicenter cohort of patients with inflammatory bowel disease treated with vedolizumab","volume":"62","author":"Allegretti","year":"2017","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2024.05.051_bib34","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.cgh.2020.07.012","article-title":"Combination therapy does not improve rate of clinical or endoscopic remission in patients with inflammatory bowel diseases treated with vedolizumab or ustekinumab","volume":"19","author":"Hu","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.05.051_bib35","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1136\/gutjnl-2022-327002","article-title":"Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn's disease","volume":"71","author":"Kirchgesner","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2024.05.051_bib36","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/ibd.20014","article-title":"Safety and tolerability of concurrent natalizumab treatment for patients with Crohn\u2019s disease not in remission while receiving infliximab","volume":"13","author":"Sands","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2024.05.051_bib38","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.05.051_bib39","first-page":"264","article-title":"The use of combination biological or small molecule therapy in inflammatory bowel disease: a retrospective cohort study","volume":"21","author":"Glassner","year":"2020","journal-title":"J\u00a0Dig Dis"},{"key":"10.1016\/j.cgh.2024.05.051_bib40","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/apt.15719","article-title":"Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn\u2019s disease","volume":"51","author":"Yang","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2024.05.051_bib41","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.cgh.2020.02.017","article-title":"Combination biologic therapy in inflammatory bowel disease: experience from a tertiary care center","volume":"19","author":"Kwapisz","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.05.051_bib42","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1016\/j.cgh.2021.03.034","article-title":"Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: a systematic review and meta-analysis","volume":"20","author":"Ahmed","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.05.051_bib43","article-title":"Systematic review with meta-analysis: safety and effectiveness of combining biologics and small molecules in inflammatory bowel disease","volume":"4","author":"Alayo","year":"2022","journal-title":"Crohns Colitis 360"},{"key":"10.1016\/j.cgh.2024.05.051_bib44","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.cgh.2023.09.010","article-title":"Vedolizumab, adalimumab, and methotrexate combination therapy in Crohn\u2019s disease (EXPLORER)","volume":"22","author":"Colombel","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Supplement_2","key":"10.1016\/j.cgh.2024.05.051_bib45","doi-asserted-by":"crossref","first-page":"ii54","DOI":"10.1093\/ecco-jcc\/jjac007","article-title":"IL-23 Blockade in anti-TNF refractory IBD: from mechanisms to clinical reality","volume":"16","author":"Atreya","year":"2022","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.05.051_bib46","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1136\/gutjnl-2017-315671","article-title":"Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn\u2019s disease","volume":"68","author":"Schmitt","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2024.05.051_bib47","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1053\/j.gastro.2020.11.038","article-title":"Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease","volume":"160","author":"Mahadevan","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.05.051_bib48","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.cell.2019.07.045","article-title":"Therapeutic opportunities in inflammatory bowel disease: mechanistic dissection of host-microbiome relationships","volume":"178","author":"Plichta","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.cgh.2024.05.051_bib49","first-page":"CD012774","article-title":"Fecal transplantation for treatment of inflammatory bowel disease","volume":"4","author":"Imdad","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cgh.2024.05.051_bib50","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41579-020-0433-9","article-title":"Gut microbiota in human metabolic health and disease","volume":"19","author":"Fan","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.cgh.2024.05.051_bib51","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.immuni.2023.01.004","article-title":"Principles of regulatory T cell function","volume":"56","author":"Dikiy","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.cgh.2024.05.051_bib52","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/gutjnl-2014-306919","article-title":"Developing in\u00a0vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn\u2019s disease","volume":"65","author":"Canavan","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2024.05.051_bib53","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1053\/j.gastro.2023.03.230","article-title":"Low-dose interleukin 2 for the treatment of moderate to severe ulcerative colitis","volume":"165","author":"Allegretti","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.05.051_bib54","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aba5264","article-title":"An IL-2 mutein engineered to promote expansion of regulatory T cells arrests ongoing autoimmunity in mice","volume":"5","author":"Khoryati","year":"2020","journal-title":"Sci Immunol"},{"key":"10.1016\/j.cgh.2024.05.051_bib55","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jcmgh.2017.03.007","article-title":"Mend your fences: the epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease","volume":"4","author":"Martini","year":"2017","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.05.051_bib56","doi-asserted-by":"crossref","first-page":"9477","DOI":"10.1073\/pnas.1921335117","article-title":"Resolvin E1 is a pro-repair molecule that promotes intestinal epithelial wound healing","volume":"117","author":"Quiros","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cgh.2024.05.051_bib57","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature13479","article-title":"Pro-resolving lipid mediators are leads for resolution physiology","volume":"510","author":"Serhan","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.cgh.2024.05.051_bib58","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat0852","article-title":"PAI-1 augments mucosal damage in colitis","volume":"11","author":"Kaiko","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cgh.2024.05.051_bib59","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/s41591-019-0393-7","article-title":"Intracellular MLCK1 diversion reverses barrier loss to restore mucosal homeostasis","volume":"25","author":"Graham","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.cgh.2024.05.051_bib60","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20192195","article-title":"The role of IL-22 in intestinal health and disease","volume":"217","author":"Keir","year":"2020","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.cgh.2024.05.051_bib61","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/S0140-6736(15)00068-9","article-title":"Early combined immunosuppression for the management of Crohn\u2019s disease (REACT): a cluster randomised controlled trial","volume":"386","author":"Khanna","year":"2015","journal-title":"Lancet"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356524006335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356524006335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T23:34:53Z","timestamp":1740612893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356524006335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1542356524006335"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2024.05.051","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IBD Matchmaking: Rational Combination Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2024.05.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the AGA Institute","name":"copyright","label":"Copyright"}]}}